title: Amino-acid-based continuous ambulatory peritoneal dialysis (CAPD) fluid over twelve weeks: effects on carbohydrate and lipid metabolism.
abstract: Aspects of lipid and carbohydrate metabolism were studied in 8 patients established on continuous ambulatory peritoneal dialysis (CAPD) with plasma albumin less than 35 g/L, before, during, and after substitution of 1 of the daily glucose exchanges by a commercial 1% amino acid dialysis fluid for 12 weeks. The amount of glucose absorbed from the dialysis fluid was consequently reduced by about 25%, hence total energy intake decreased by about 100 Kcal/day, but peritoneal glucose transfer kinetics were unaffected. Glucose was lost into amino acid dialysate as expected (2 g/day). Excluding 1 patient with a large rise in calorie intake, total and LDL cholesterol fell at 8 and 12 weeks (LDL cholesterol week 0, 5.26 +/- 1.13; week 8, 4.32 +/- 0.74; week 12, 4.30 +/- 1.22; mean +/- SD, p less than 0.01 for both), but returned to baseline 2 weeks after the restoration of glucose fluid (LDL 4.91 +/- 1.22, p less than 0.05 vs. week 12). Apolipoprotein B concentration also fell at 12 weeks (p less than 0.01). No changes were seen in body weight, body fat, arm muscle circumference, fasting plasma glucose, insulin, growth hormone, triglyceride, nonesterified fatty acids, or HDL cholesterol. The response of these biochemical indices to single 8-h glucose and amino acid morning exchanges at 0 and 12 weeks were studied. After 12 week's use of amino acid dialysis fluid, plasma cholesterol and apolipoprotein B were significantly lower throughout the exchange.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Renal Unit, General Infirmary at Leeds, United Kingdom.
authors.forename: J B
authors.initials: JB
authors.lastname: Dibble
authors.forename: G A
authors.initials: GA
authors.lastname: Young
authors.forename: S M
authors.initials: SM
authors.lastname: Hobson
authors.forename: A M
authors.initials: AM
authors.lastname: Brownjohn
mesh_terms: D000596:Amino Acids / Q000008:administration & dosage*; D001055:Apolipoproteins B / Q000097:blood*; D001786:Blood Glucose / Q000032:analysis*; D002784:Cholesterol / Q000097:blood*; D015314:Dialysis Solutions; D002149:Energy Intake; D005260:Female; D005947:Glucose / Q000493:pharmacokinetics; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D013997:Time Factors
chemical_list: D000596:Amino Acids; D001055:Apolipoproteins B; D001786:Blood Glucose; D015314:Dialysis Solutions; D002784:Cholesterol; D005947:Glucose